Bikramajit Singh Saroya

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Wafik S El-Deiry, W. El-Deiry, Zhaohai Yang, 2013, Cancer biology & therapy.